Ocular Therapeutix (OCUL) Proxy filing summary

Voting matters and shareholder proposals

• Election of two Class III directors to serve until the 2029 annual meeting and until successors are elected and qualified.

• Advisory vote to approve named executive officer compensation.

• Advisory vote on the frequency of future say-on-pay votes, with a recommendation for annual votes.

• Approval of an amendment to the 2021 Stock Incentive Plan to increase shares issuable by 10,000,000.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Nominees for director election are Pravin U. Dugel, M.D. and Merilee Raines.

• Directors to serve until 2029 annual meeting if elected.

Executive compensation and say-on-pay

• Advisory vote on executive compensation is included as a key agenda item.

• Shareholders to vote on the frequency of future say-on-pay votes.